Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Bayer Aktienges ADR
(OP:
BAYRY
)
4.880
-0.030 (-0.61%)
Streaming Delayed Price
Updated: 3:59 PM EST, Dec 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Bayer Aktienges ADR
< Previous
1
2
3
4
5
6
Next >
Dyadic Intl. Inc. (NASDAQ: DYAI) Potential Strategic Alliances with Future of Foods Boosts Stock as Key Conference Looms
March 19, 2024
Via
AB Newswire
Topics
Supply Chain
Exposures
Supply Chain
Bayer's Third Menopausal Relief Drug Trial Meets Primary Goal, German Conglomerate Seeks FDA Approval For Elinzanetant
March 19, 2024
Bayer's Phase 3 study OASIS 3 findings on elinzanetant, a promising non-hormonal treatment for menopausal hot flashes. Results show significant reduction in symptoms over 12 weeks, marking a potential...
Via
Benzinga
Exposures
Product Safety
German Conglomerate Bayer Goes Johnson & Johnson Way To Tackle Its Cancer Related Lawsuits
March 14, 2024
Bayer contemplates Texas Two-Step bankruptcy to tackle Roundup lawsuits in the US amid mounting jury verdicts. Learn about the controversial tactic and its potential implications.
Via
Benzinga
Topics
Bankruptcy
Lawsuit
Exposures
Financial
Glyphosate
Legal
BAYRY Stock Earnings: Bayer Beats EPS, Misses Revenue for Q4 2023
March 05, 2024
BAYRY stock results show that Bayer beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023.
Via
InvestorPlace
Bayer Holds Splitting Into Separate Units For Three Years, Focus Shifts On Tackling Challenges
March 05, 2024
Bayer charts strategic course amid structural evaluation. CEO Bill Anderson addresses group's challenges, prioritizing performance and flexibility. The company's focus and fiscal outlook for 2024.
Via
Benzinga
Biotechs on the Rise: 3 Stocks to Buy for a Shot of Profits
March 04, 2024
Given recent industry performance, the enthusiasm investors have for biotech stocks to buy is low. But these three companies seem promising.
Via
InvestorPlace
What's Going On With BridgeBio Pharma Stock On Monday?
March 04, 2024
BridgeBio Pharma partners with Bayer on acoramidis for ATTR-CM in Europe. $310 million deal, FDA application accepted.
Via
Benzinga
Exposures
Product Safety
BridgeBio, A Top 3% Biotech, Just Snagged A $310 Million Deal; Will Shares Break Out?
March 04, 2024
BridgeBio will receive a tiered royalty on sales that begins at the low-30% range.
Via
Investor's Business Daily
Cathie Wood Just Bought These 3 Biotech Stocks. Should You Buy, Too?
March 01, 2024
On the leading edge of rare disease treatment and therapy is where you will find these Cathie Wood biotech stocks.
Via
InvestorPlace
3 Overextended Stocks That Need to Slash Their Dividends ASAP
February 27, 2024
The most common attribute of overextended stocks other than carrying too much debt is dividends that are too big.
Via
InvestorPlace
MAIA Biotechnology: Undervalued With Eye-Popping Cancer Data And Partnership Potential
February 22, 2024
MAIA Biotechnology, a biotechnology company developing innovative cancer treatments, has seen its stock drift downwards for the past months.
Via
Talk Markets
Week In Review: I-Mab Morphs Into US-Only Company; Sells China Assets For $80 Million
February 11, 2024
I-Mab will become a completely US-based company, divesting itself of I-Mab Biopharma (Hangzhou), an unconsolidated affiliate. I-Mab Hangzhou will acquire rights to I-Mab’s drug assets in Greater China...
Via
Talk Markets
Weedkiller Woes: Australian Court Nears Decision in Bayer's Roundup Trial
January 30, 2024
Follow the landmark Australian Roundup lawsuit against Bayer. Closing arguments in class action alleging Roundup's link to cancer.
Via
Benzinga
Topics
Lawsuit
Exposures
Financial
Glyphosate
Legal
Roundup Cancer Verdict: Woes Continue For Bayer As It Faces $2.2B Payout
January 29, 2024
"Bayer's Monsanto ordered to pay $2.2 billion in Roundup cancer case. Explore the landmark verdict, compensatory losses, and punitive damages.
Via
Benzinga
Exposures
Glyphosate
Week In Review: China Biopharmas Book $9 Billion In Deals During JP Morgan Conference Week
January 13, 2024
Shanghai Argo Biopharma entered 2 agreements with Novartis, out-licensing four next-gen RNAi therapeutics for $185 million upfront and a total value of $4.2 billion. Additionally, Ambrx Biopharma will...
Via
Talk Markets
Large Drugmakers Show Enthusiasm To Embrace $100B Obesity Market, Despite Novo And Lilly's Dominance
January 11, 2024
Pharmaceutical companies, including Amgen Inc (NASDAQ: AMGN) and Pfizer Inc (NYSE: PFE), are strategically positioning themselves to tap into the
Via
Benzinga
Menopause Management: Bayer's Non-Hormonal Treatment Option Shows Efficacy In Trial
January 08, 2024
Monday, Bayer AG (OTC: BAYRY (OTC: BAYZF)
Via
Benzinga
Bayer Study On Parkinson's Disease Gene Therapy Succeeds In Early-Stage Trial
January 04, 2024
Bayer completed an 18-month data collection in the Phase Ib trial for a gene therapy for treating patients with Parkinson's.
Via
Benzinga
Top Stocks, Sectors Loved By Congress Members Who Traded In 2023: Apple, NVIDIA, Microsoft, Ford And More Stocks To Watch In 2024
January 03, 2024
One of the hottest topics among members of Congress and investors has been the stock and options trading activity by several politicians.
Via
Benzinga
Best 4 Agriculture Companies For Your 2024 Investment Portfolio
December 27, 2023
Agriculture is and remains, a crucial sector for sustaining life, offering investors diverse opportunities in this vital industry.
Via
Talk Markets
Legal Victory For Bayer: Roundup Lawsuit Ends Five-Trial Losing Streak
December 26, 2023
In a significant turn of events, Bayer AG (OTC: BAYRY) (OTC: BAYZF) emerged victorious in a California lawsuit filed by Bruce Jones, who alleged that the use of Roundup caused his non-Hodgkin...
Via
Benzinga
Topics
Lawsuit
Exposures
Financial
Glyphosate
Legal
ESG Stocks Take Center Stage As Damages From Climate-Related Events Rise Exponentially Within US
December 19, 2023
With climate change becoming a mega market force, ESG investing is rising. The XVV is up 28% YTD. Agri-Tech stocks like Bayer AG, FMC Corporation, and Corteva Inc are providing climate resilience...
Via
Benzinga
Topics
Climate Change
Exposures
Climate
AI Meets Biotech: 3 Top Stocks Transforming Medical Science
December 16, 2023
The AI revolution is bringing big gains to biotechnology, including drugs, antibodies, and synthetic biology.
Via
InvestorPlace
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Bayer Faces $3.5M Verdict in Fifth Consecutive Roundup Weedkiller Loss
December 06, 2023
Bayer AG (OTC: BAYRY) (OTC:
Via
Benzinga
Exposures
Glyphosate
Bayer Faces Growing Pressure Amid Roundup Lawsuits as Philadelphia Trial Nears Conclusion
December 04, 2023
The spotlight is on a Philadelphia trial as Bayer AG (OTC: BAYRY) (OTC: BAYZF) grapples with mounting legal challenges surrounding its Roundup weedkiller, prompted by multi-billion dollar verdicts
Via
Benzinga
Topics
Lawsuit
Exposures
Financial
Glyphosate
Legal
PFAS's Forever Problem: Ohio Lawsuit Against Chemical Companies Fizzles Out
November 28, 2023
Big chemical companies won a lawsuit preventing 11.8 million Ohio residents from suing them for PFAS chemicals in their blood.
Via
Benzinga
Topics
Lawsuit
Exposures
Financial
Legal
3 Battered Blue-Chip Stocks to Sell in December
November 28, 2023
Steer clear of these once flourishing companies, each of which has problems they need to overcome before their share price rises again.
Via
InvestorPlace
German Conglomerate Bayer Faces Investor Scrutiny Amid Unexpected Legal, Trial Setbacks
November 24, 2023
Bayer AG (OTC: BAYRY) (OTC: BAYZF) reportedly held an investor call to address concerns after intense scrutiny from investors following a series of unforeseen setbacks, prompting questions about...
Via
Benzinga
Analyst Assess Implications of Bristol Myers' Investigational Blood Thinner Post Bayer Trial Setback Amid Shaken Investor Confidence
November 20, 2023
Monday, Bayer AG (OTC: BAYRY) (OTC: BAYZF)
Via
Benzinga
Bayer's Blood Thinner Study Stopped Early Due To Lack Of Efficacy: Details
November 20, 2023
Bayer AG (OTC: BAYRY) (OTC: BAYZF)
Via
Benzinga
< Previous
1
2
3
4
5
6
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.